Soluble and membrane‐bound interleukin (IL)‐15 Rα/IL‐15 complexes mediate proliferation of high‐avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections

The lack of persistence of infused T cells is a principal limitation of adoptive immunotherapy in man. Interleukin (IL)‐15 can sustain memory T cell expansion when presented in complex with IL‐15Rα (15Rα/15). We developed a novel in‐vitro system for generation of stable 15Rα/15 complexes. Immunologically quantifiable amounts of IL‐15 were obtained when both IL‐15Rα and IL‐15 genes were co‐transduced in NIH 3T3 fibroblast‐based artificial antigen‐presenting cells expressing human leucocyte antigen (HLA) A:0201, β2 microglobulin, CD80, CD58 and CD54 [A2‐artificial antigen presenting cell (AAPC)] and a murine pro‐B cell line (Baf‐3) (A2‐AAPC15Rα/15and Baf‐315Rα/15). Transduction of cells with IL‐15 alone resulted in only transient expression of IL‐15, with minimal amounts of immunologically detectable IL‐15. In comparison, cells transduced with IL‐15Rα alone (A2‐AAPCRα) demonstrated stable expression of IL‐15Rα; however, when loaded with soluble IL‐15 (sIL‐15), these cells sequestered 15Rα/15 intracellularly and also demonstrated minimal amounts of IL‐15. Human T cells stimulated in vitro against a viral antigen (CMVpp65) in the presence of 15Rα/15 generated superior yields of high‐avidity CMVpp65 epitope‐specific T cells [cytomegalovirus‐cytotoxic T lymphocytes (CMV‐CTLs)] responding to ≤ 10− 13 M peptide concentrations, and lysing targets cells at lower effector : target ratios (1 : 10 and 1 : 100), where sIL‐15, sIL‐2 or sIL‐7 CMV‐CTLs demonstrated minimal or no activity. Both soluble and surface presented 15Rα/15, but not sIL‐15, sustained in‐vitro expansion of CD62L+ and CCR7+ central memory phenotype CMV‐CTLs (TCM). 15Rα/15 complexes represent a potent adjuvant for augmenting the efficacy of adoptive immunotherapy. Such cell‐bound or soluble 15Rα/15 complexes could be developed for use in combination immunotherapy approaches.

[1]  R. O'reilly,et al.  Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  B. Deslouches,et al.  Memory T Cells Specific for Murine Cytomegalovirus Re-Emerge after Multiple Challenges and Recapitulate Immunity in Various Adoptive Transfer Scenarios , 2015, The Journal of Immunology.

[3]  D. Campana,et al.  Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. , 2014, Blood.

[4]  Christian Stemberger,et al.  Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy. , 2014, Blood.

[5]  R. Fairchild,et al.  IL‐15 Induces Alloreactive CD28− Memory CD8 T Cell Proliferation and CTLA4‐Ig Resistant Memory CD8 T Cell Activation , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  Fella Tamzalit,et al.  IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells , 2014, Proceedings of the National Academy of Sciences.

[7]  H. Wong,et al.  Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma. , 2013, Cancer research.

[8]  J. Lifson,et al.  Characterization and Favorable in Vivo Properties of Heterodimeric Soluble IL-15·IL-15Rα Cytokine Compared to IL-15 Monomer* , 2013, The Journal of Biological Chemistry.

[9]  B. Engels,et al.  IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner , 2013, Proceedings of the National Academy of Sciences.

[10]  H. Heslop,et al.  Interleukin 15 Provides Relief to CTLs from Regulatory T Cell–Mediated Inhibition: Implications for Adoptive T Cell–Based Therapies for Lymphoma , 2012, Clinical Cancer Research.

[11]  U. Gerdemann,et al.  Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections , 2012, Molecular Therapy.

[12]  T. Waldmann,et al.  Augmented IL-15Rα Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice , 2012, The Journal of Immunology.

[13]  G. Altan-Bonnet,et al.  Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. , 2012, Blood.

[14]  T. Waldmann,et al.  Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model , 2012, Proceedings of the National Academy of Sciences.

[15]  J. Teruya-Feldstein,et al.  Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. , 2012, Blood.

[16]  P. Greenberg,et al.  Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy , 2011, Cancer Immunology, Immunotherapy.

[17]  H. Einsele,et al.  Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. , 2010, Blood.

[18]  T. Waldmann,et al.  Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model , 2010, Clinical Cancer Research.

[19]  Leesun Kim,et al.  Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets. , 2009, Immunity.

[20]  T. Wu,et al.  Expression of IL‐15RA or an IL‐15/IL‐15RA fusion on CD8+ T cells modifies adoptively transferred T‐cell function in cis , 2009, European journal of immunology.

[21]  J. Sprent,et al.  Homeostasis of naive and memory T cells. , 2008, Immunity.

[22]  Jianhong Cao,et al.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.

[23]  A. Ma,et al.  IL-15Rα chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation , 2008, The Journal of experimental medicine.

[24]  R. Bronson,et al.  Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. , 2008, Cancer research.

[25]  K. Kane,et al.  IL-15 Transpresentation Augments CD8+ T Cell Activation and Is Required for Optimal Recall Responses by Central Memory CD8+ T Cells1 , 2008, The Journal of Immunology.

[26]  G. Pavlakis,et al.  Intracellular Interaction of Interleukin-15 with Its Receptor α during Production Leads to Mutual Stabilization and Increased Bioactivity* , 2008, Journal of Biological Chemistry.

[27]  Mike Gough,et al.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.

[28]  I. Kang,et al.  Dual Roles of IL-15 in Maintaining IL-7RαlowCCR7− Memory CD8+ T Cells in Humans via Recovering the Phosphatidylinositol 3-Kinase/AKT Pathway1 , 2007, The Journal of Immunology.

[29]  T. Waldmann,et al.  The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells , 2007, Proceedings of the National Academy of Sciences.

[30]  L. Lefrançois,et al.  Combined IL-15/IL-15Rα Immunotherapy Maximizes IL-15 Activity In Vivo1 , 2006, The Journal of Immunology.

[31]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[32]  T. Waldmann,et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[34]  S. Rosenberg,et al.  Survival, Persistence, and Progressive Differentiation of Adoptively Transferred Tumor-Reactive T Cells Associated with Tumor Regression , 2005, Journal of immunotherapy.

[35]  M. Caligiuri,et al.  Failed Adoptive Immunotherapy with Tumor-Specific T Cells , 2004, Cancer Research.

[36]  S. Rosenberg,et al.  Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Burkett,et al.  Coordinate Expression and Trans Presentation of Interleukin (IL)-15Rα and IL-15 Supports Natural Killer Cell and Memory CD8+ T Cell Homeostasis , 2004, The Journal of experimental medicine.

[38]  L. Lefrançois,et al.  Transregulation of memory CD8 T-cell proliferation by IL-15Ralpha+ bone marrow-derived cells. , 2004, Blood.

[39]  Paula Kavathas,et al.  Interplay between TCR Affinity and Necessity of Coreceptor Ligation: High-Affinity Peptide-MHC/TCR Interaction Overcomes Lack of CD8 Engagement 1 , 2003, The Journal of Immunology.

[40]  Leo Lefrançois,et al.  Cytokine control of memory T-cell development and survival , 2003, Nature Reviews Immunology.

[41]  J. Berzofsky,et al.  Selective Induction of High Avidity CTL by Altering the Balance of Signals from APC , 2003, The Journal of Immunology.

[42]  Rustom Antia,et al.  Lineage relationship and protective immunity of memory CD8 T cell subsets , 2003, Nature Immunology.

[43]  T. Waldmann,et al.  IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells , 2002 .

[44]  L. Lefrançois,et al.  Cutting Edge: Requirement for IL-15 in the Generation of Primary and Memory Antigen-Specific CD8 T Cells1 , 2002, The Journal of Immunology.

[45]  E. Pamer,et al.  Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors. , 2002, Blood.

[46]  J. Sprent,et al.  Generation and maintenance of memory CD4(+) T Cells. , 2001, Current opinion in immunology.

[47]  T. Waldmann,et al.  Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. , 2001, Immunity.

[48]  Michel Sadelain,et al.  Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells , 2000, Nature Biotechnology.

[49]  P. Morrissey,et al.  Reversible Defects in Natural Killer and Memory Cd8 T Cell Lineages in Interleukin 15–Deficient Mice , 2000, The Journal of experimental medicine.

[50]  J. Sprent,et al.  Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. , 1998, Immunity.

[51]  C. Pitcher,et al.  Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. , 1997, The Journal of clinical investigation.

[52]  Malcolm K. Brenner,et al.  Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.

[53]  David Gray,et al.  Immunological Memory and Protective Immunity: Understanding Their Relation , 1996, Science.

[54]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[55]  M. Collins,et al.  Regulation of apoptosis in interleukin‐3‐dependent hemopoietic cells by interleukin‐3 and calcium ionophores. , 1990, The EMBO journal.

[56]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[57]  M. Kozak,et al.  At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. , 1987, Journal of molecular biology.

[58]  M. Sadelain,et al.  Adoptive Therapy and Subdominant Viral Epitopes for Cytotoxic T Cells Specific for Both Dominant Prevalent HLA Alleles Permits Generation of A Panel of Artificial APCs Expressing , 2009 .

[59]  Leo Lefrançois,et al.  Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. , 2006, Journal of immunology.

[60]  T. Waldmann,et al.  IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. , 2002, Immunity.

[61]  J. Sprent,et al.  Generation and maintenance of memory T cells. , 2001, Current opinion in immunology.